Mitsubishi UFJ Asset Management Co. Ltd. Acquires 309,681 Shares of AbbVie Inc. $ABBV

Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 7.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,340,720 shares of the company’s stock after buying an additional 309,681 shares during the quarter. AbbVie comprises 0.6% of Mitsubishi UFJ Asset Management Co. Ltd.’s portfolio, making the stock its 29th biggest holding. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in AbbVie were worth $1,092,299,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ABBV. State Street Corp raised its stake in shares of AbbVie by 1.4% in the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after acquiring an additional 1,119,274 shares in the last quarter. Geode Capital Management LLC grew its holdings in AbbVie by 10.4% during the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after purchasing an additional 4,190,487 shares during the last quarter. Bank of America Corp DE grew its holdings in AbbVie by 1.4% during the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock valued at $5,900,617,000 after purchasing an additional 356,394 shares during the last quarter. Norges Bank bought a new position in shares of AbbVie in the fourth quarter valued at approximately $5,865,055,000. Finally, Capital Research Global Investors raised its position in shares of AbbVie by 0.7% in the fourth quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock valued at $5,805,530,000 after purchasing an additional 177,370 shares during the period. 70.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective for the company in a report on Thursday, August 13th. Cantor Fitzgerald boosted their target price on shares of AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. JPMorgan Chase & Co. upped their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. Finally, Piper Sandler lifted their price objective on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $275.95.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of SKYRIZI in adults with moderately to severely active Crohn’s disease. The filing, supported by positive Phase 3 AFFIRM data, could expand SKYRIZI’s European Crohn’s disease label and offer patients a less invasive alternative to intravenous induction. AbbVie Submits Regulatory Application to EMA for SKYRIZI Subcutaneous Induction
• Positive Sentiment: The company’s inclusion in articles highlighting reliable dividend stocks reinforces AbbVie’s appeal to income-focused investors. Its dividend profile and defensive healthcare exposure may provide support, particularly during periods of economic or inflation uncertainty. 3 Dividend Stocks, 12 Paychecks a Year
• Positive Sentiment: Ken Griffin reportedly increased his AbbVie stake by 547% during the second quarter, signaling confidence from a prominent institutional investor in the company’s dividend and long-term prospects. Ken Griffin Increased His Stake in AbbVie
• Neutral Sentiment: AbbVie’s patient-support efforts, including an immunology scholarship program, strengthen its public-facing support initiatives but are unlikely to materially affect near-term earnings or valuation. AbbVie’s Immunology Scholarship Program
• Negative Sentiment: Valuation concerns may be limiting upside. AbbVie has rallied significantly and is trading at a premium, prompting debate over whether future growth from SKYRIZI and the broader pipeline can justify the stock’s price. Has AbbVie Stock Become Too Expensive to Buy?

AbbVie Trading Down 1.8%

Shares of ABBV stock opened at $258.23 on Friday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47. The firm’s fifty day simple moving average is $251.87 and its 200 day simple moving average is $228.68. The firm has a market capitalization of $456.24 billion, a P/E ratio of 72.95, a price-to-earnings-growth ratio of 0.87 and a beta of 0.30.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 14.06 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.